Personalis Revenue and Competitors
Estimated Revenue & Valuation
- Personalis's estimated annual revenue is currently $57.7M per year.
- Personalis received $33.0M in venture funding in January 2015.
- Personalis's estimated revenue per employee is $168,105
- Personalis's total funding is $225.1M.
Employee Data
- Personalis has 343 Employees.
- Personalis grew their employee count by -14% last year.
Personalis's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | CFO and COO | Reveal Email/Phone |
3 | VP People and CHRO | Reveal Email/Phone |
4 | SVP Regulatory, Quality and Clinical Compliance | Reveal Email/Phone |
5 | VP, Diagnostic Sales | Reveal Email/Phone |
6 | VP, Quality Assurance, Regulatory Compliance & Clinical Laboratories | Reveal Email/Phone |
7 | VP Sales - DX | Reveal Email/Phone |
8 | Head Tax and Treasury | Reveal Email/Phone |
9 | SVP, Genomic Laboratory Operations | Reveal Email/Phone |
10 | VP, General Counsel & Corporate Secretary | Reveal Email/Phone |
Personalis Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $343.9M | 3176 | 7% | $550M | $7.9B |
#2 | $434.8M | 1865 | -14% | $2B | $2.7B |
What Is Personalis?
Personalis, Inc. is partnering with biopharma to develop and commercialize the next generation of cancer immunotherapies. We provide advanced genomic sequencing and analytics for immuno-oncology. Our patented ACE (Accuracy and Content Enhanced) Technology forms the foundation of all Personalis products and makes it possible for us to achieve augmented coverage of difficult-to-sequence genomic regions often missed with the use of conventional sequencing techniques, for more comprehensive and accurate genomic data. ACE ImmunoID, our universal platform for immuno-oncology, combines augmented whole exome and transcriptome assays with analytics that capture neoantigens, elucidate the tumor microenviroment, and identify mechanisms of tumor escape. The company's Clinical Laboratory is GxP aligned as well as CLIA88 and CAP accredited. To learn more, visit us at www.personalis.com and follow us on Twitter @personalisinc.
keywords:Biotechnology,Healthcare,Medical Diagnostics,Pharmaceuticals
$225.1M
Total Funding
343
Number of Employees
$57.7M
Revenue (est)
-14%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Personalis News
Overall, Personalis has 19 issued US and foreign patents, spanning 16 distinct families, relating to advanced genomic sequencing and analysis...
Personalis Publishes New Data Demonstrating Highly Sensitive Algorithm for Detecting Loss of Heterozygosity in HLA Gene. Tool detects...
Personalis and Merck KGaA, Darmstadt, Germany to Present Comprehensive Tumor Subtyping Collaboration Data at AACR Annual Meeting 2022. Profiling...
NEW YORK – Cancer sequencing firm Personalis reported after the close of the market on Tuesday that its second quarter 2019 revenues were ...
Other Companies in Menlo Park
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $102.1M | 363 | 17% | $80.1M |
#2 | $86M | 382 | N/A | N/A |
#3 | $63.2M | 383 | 67% | $106.3M |
#4 | $120.1M | 392 | 3% | N/A |
#5 | $106.9M | 401 | 16% | $518M |
Personalis Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2013-10-07 | $22.0M | B | Abingworth | Article |
| 2015-01-05 | $29.6M | Undisclosed | Article | |
| 2015-01-14 | $33.0M | C | Lightspeed Venture Partners | Article |